Books I have edited that may be of interest to those who study cancer. They are all available on Amazon.
“Cancer Knows No Boundaries”
As Politicians Argue About China, US Patients Find Cutting-Edge Treatment There
kffhealthnews.org/health-ind…
Wafik S. El-Deiry, MD, PhD, FACP retweeted
In January 2025 my mom’s lung cancer spread to her brain. The drug with the best chance of helping her was approved in China but not here.
A doctor told me, almost as an aside, that if she were Chinese she could buy it at a pharmacy.
So I flew to Shanghai and came home with 26 boxes in my luggage. That was 19 months ago. My mom is still here, still working, and in her words has had an amazing three years.
The drug was approved in China in 2023. The FDA approved it in July 2025. It still is not for sale here. I know of at least 30 Americans who have made the same trip.
I have been scared to tell this story because I worried it could cost my mom access to the medicine keeping her alive. But the problem matters more than my silence. These drugs need to be developed and available here, and that means FDA reform.
Art Allen at KFF Health News told our story this week. It also ran in The Washington Post.
kffhealthnews.org/health-ind…
In the news from China and Peking University👇
Cell publisher investigates editor accused of soliciting bribes from China
Probe triggered by social media post in which prominent biologist singled out Chinese-born editor-in-chief of medical journal Cancer Cell
scmp.com/news/china/science/…
Wafik S. El-Deiry, MD, PhD, FACP retweeted
Prominent Chinese biologist Rao Yi accused the editor-in-chief of a top medical journal of soliciting bribes
scmp.com/news/china/science/…
Wafik S. El-Deiry, MD, PhD, FACP retweeted
Replying to @deniswirtz
Recently submitted 2 #eldeirylab papers to @Cancer_Cell checked off open access fee of >$8,000/paper. Neither paper sent for review & I transferred both to another Cell Press journal with open access fee of >$5,000/paper. Next will plan on @biorxivpreprint, will be 1st in future.
Wafik S. El-Deiry, MD, PhD, FACP retweeted
🚨 DAVID M. SABATINI — FROM A POTENTIAL NOBEL LAUREATE TO NEARLY SIX YEARS OF PROFESSIONAL DESTRUCTION AND PERSONAL SUFFERING
$6 MILLION IN DAMAGES — BUT WHO CAN RESTORE NEARLY SIX LOST YEARS OF AN EXCEPTIONAL SCIENTIST'S LIFE?
@DMSabatini was once among the world's most celebrated biomedical scientists. His pioneering discovery of the mTOR signaling pathway transformed our understanding of cellular growth, metabolism, aging, and cancer.
By 2018, he was being discussed as a promising candidate for a future Nobel Prize. In 2020, he received the prestigious Sjöberg Prize from the Royal Swedish Academy of Sciences.
Then, his world began to collapse.
Late 2020–2021: In October 2020, Kristin Knouse accused Sabatini of sexual harassment. Whitehead then ran an institute-wide climate survey. These steps led to an outside investigation.*
* Participation from Sabatini’s lab (~40 people) was low — roughly five responses. Some lab members later said investigators pressured them to give negative accounts.
August 20, 2021: The investigation found Sabatini violated Whitehead’s policies on sexual harassment and relationships. He resigned from the Whitehead Institute, was fired by HHMI, and was placed on leave by MIT.
April 1, 2022: He resigned from MIT after officials recommended revoking his tenure. Later that month NYU considered hiring him; organized campus protests followed and he withdrew in early May.
A scientist who had spent decades building an extraordinary research career was suddenly confronted with professional isolation, public condemnation, lost opportunities, and the dismantling of the institutional foundations supporting his research.
The damage extended far beyond his appointments. It consumed years of his life, disrupted his scientific contributions, and subjected him to an ordeal whose personal consequences cannot be measured in financial terms.
OCTOBER 16, 2026 — THE VERDICT
After nearly six years of controversy and five years of litigation, a Massachusetts civil jury found that his former colleague, Kristin Knouse, had DEFAMED HIM AND TORTIOUSLY INTERFERED WITH HIS PROFESSIONAL RELATIONSHIPS, rejected her counterclaims, and awarded Sabatini $6 MILLION IN DAMAGES, with additional interest.
His first public reaction was devastating in its simplicity:
“Today I smiled for real for the first time in more than 5 years.”
⚠️ SIX MILLION DOLLARS?
What monetary award can compensate for nearly six years of suffering, professional exclusion, shattered opportunities, and the interruption of a potentially Nobel Prize–winning scientific career?
Money cannot return lost years. It cannot undo the anguish. It cannot recreate the discoveries that might have been made, the students who might have been trained, or the scientific advances that might have emerged.
🔱 SCIENCEGUARDIANS™ — THE ANATOMY OF A COORDINATED REPUTATION-DESTRUCTION CAMPAIGN
Between May 25 and 31, 2026, ScienceGuardians™ published its seven-part investigative series exposing the mechanisms through which academic leaders can be subjected to systematic reputation destruction (🔗 see the link to the full investigative thread in the first comment):
Target Selection → Recruitment of Insiders → Weaponization of Partial Truths → Media Amplification → Institutional Pressure → Reputation Collapse → Forced Resignation.
The chronology of Sabatini's ordeal reveals disturbing parallels with all seven stages of the coordinated reputation-destruction framework exposed by ScienceGuardians™.
For years, ScienceGuardians™ has been investigating the activities of the perpetrators we have identified within the PubPeer “PubSmear” Network Mob, alongside the damaging role that reckless or compromised journalists and editors can play in academic reputation-destruction campaigns.
We are examining the extent to which these external actors contributed to the public narratives and institutional pressures surrounding Sabatini's case. Their specific involvement and any coordination must be established through documentary evidence, and our investigation will continue to scrutinize these questions.
⚠️ Malicious reputation attacks and compromised journalism are among the gravest threats to academic integrity. When allegations are amplified without sufficient scrutiny, the resulting institutional consequences can become irreversible long before the underlying facts are fully tested.
The Sabatini verdict is a powerful reminder that accusations are not convictions, public condemnation is not due process, and reputational destruction is not scientific integrity.
We stand firmly for the right of every scientist to fair treatment, independent scrutiny of allegations, and meaningful accountability when defamation is established.
David M. Sabatini has won a significant legal victory. But no jury can give him nearly six years of his life back—or restore to humanity the invaluable scientific contributions he might have made during those lost years.
@SciGuardians 🔱
Appreciate very interesting presentation this morning by Professor Shengliang Zhang @shengliang15 at #eldeirylab group meeting of an interesting paper in the October 1, 2026 issue of @ScienceMagazine
Loss of the tumor suppressor p53 generates a signaling gradient that drives epithelial clonal expansion
“p53 restrains epithelial colonization by maintaining a network that controls both the strength and spatial organization of
Wnt signaling. Its loss creates a radial Wnt activity gradient that is associated with sustained progenitor self- renewal and rapid clonal expansion. These findings show that the spatial pattern of a growth signal, not only its overall level, can determine how mutant cells
spread through normal tissue.”
“Trp53−/− clones sustain a higher rate of progenitor renewal at the center than at the edges and in surrounding WT cells, enabling sustained expansion over time. This mode of growth contrasts with that
of HrasG12V mutant clones, which exhibit lower renewal at the center
than at the edge.”
science.org/doi/10.1126/scie…
I am reminded of a classical paper in Science in 2000 “Hematopoietic stem cell quiescence maintained by p21cip1/waf1” pubmed.ncbi.nlm.nih.gov/1071… and would suspect that loss of p21(WAF1) regulation by p53 in a state of p53 deficiency might contribute to a more proliferative state in the presence of Wnt activation.
I am also reminded of a paper from 3 decades ago “p53-independent transcriptional activation of p21 by vitamin D3 “Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937” genesdev.cshlp.org/content/1…
Such control as summarized in “Vitamin D and the skin: Physiology and pathophysiology” pmc.ncbi.nlm.nih.gov/article… “Regulation of these actions is exerted by a number of different coregulator complexes including the coactivators vitamin D receptor interacting protein (DRIP) complex also known as Mediator and the steroid receptor coactivator (SRC) family (of which SRC 2 and 3 are found in keratincytes), the inhibitor hairless (Hr), and β-catenin whose impact on VDR function is complex.”
Thus there is complex regulation of skin proliferation and one would hope future studies will investigate and discuss in more depth the complex regulatory networks that involve, growth, differentiation and cancer in p53-dependent and -independent pathways in epidermis and other tissues that also look at role of p53 family members.
science.org/doi/10.1126/scie…
@theNCI @AACR @AmericanCancer @BrownUniversity @ASCO @WIN_Consortium @Dr_R_Kurzrock @AACRPres @VivekSubbiah @SewantiLimaye @NCIDirector
Practical Review of Role and Usage of Corticosteroids in Modern Neuro-Oncology Care
neurology.org/doi/10.1212/CP…
Wafik S. El-Deiry, MD, PhD, FACP retweeted
I'm a Board Certified anesthesiologist and have been in practice for 24 years. I just learned that the Children's Hospital of Philadelphia where I trained has launched a program to increase flu vaccine uptake among children by vaccinating them while under anesthesia.
The program is called "Close your Eyes. We'll Immunize"
This is stunningly irresponsible. Here's why:
Anesthetists are extremely risk avoidant and endeavor to minimize patient exposure to anything which carries potential side effects. This is particularly true of pediatric patients who very often have never been exposed to anesthetic medications. We simply cannot know how an individual child will respond to these drugs for the first time.
Every single medication we administer during an operation can potentially trigger untoward or allergic responses. When this occurs our primary responsibility is to stabilize the patient. Our secondary responsibility is to identify the offending agent. There is absolutely no justification of introducing another agent, in this case a flu vaccine, which carries a risk of harm and contributes nothing to the success of the operation.
Some of the more common side effects of flu vaccines are fever (11-16%) and less commonly, a rash (1%). There is also an non-zero risk of severe allergic reactions and high-grade fevers which can develop over the course of minutes.
What if a child under anesthesia receives a vaccine and develops a rash and/or fever? Is it from the antibiotic that the surgeon requested? Is it from the narcotic? The anxiolytic? The barbiturate?
Anesthetic gases can also (rarely) trigger a life threatening response called Malignant Hyperthermia which commonly presents as a high fever. Without subsequent testing we cannot know which agent was responsible. Most commonly the testing is never done and the child’s record will forever reflect the possibility that some or all of the drugs which were used are responsible for their reaction. This makes future anesthetic care significantly more challenging and will require the use of alternatives which may not be necessary.
Advocating for a flu vaccine while a child is anesthetized reflects the pervasive yet inaccurate attitude among the medical establishment that vaccines are perfectly safe. I simply cannot believe that my mentors would have ever supported this initiative when I was a resident there. Close your eyes indeed.
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
nejm.org/doi/full/10.1056/NE…
Learning this evening at my @KelleyBizMed accounting class A524 taught by Professor Reed Smith about Time-Driven Activity-Based Costing (TDABC) Process Mapping that was piloted at @UTMDAnderson as they transitioned towards Value-Based Healthcare (VBHC) 15 years ago. (I looked up the history of this case study as the class focused on other examples for example at Boston Children’s Hospital and Harvard Business Review).
p53-Therapeutics, Inc., a Major Sponsor of 2026 WIN Symposium in Rhode Island, October 2-3, 2026, co-Hosted Welcome Reception, Presented Precision Oncology Research, and Participated in Industry Panel at the recently held global precision oncology conference at the Rhode Island Convention Center.
The leadership of p53-Therapeutics participated in an Industry Perspectives Session chaired by Bob Cormier, President and CEO of the Rhode Island Life Science Hub (RILSH).
Bradley Sander, Chief Executive Officer, and Emile Youssef, MD, PhD, Chief Medical Officer, served on the panel “Industry Perspectives: Genomic Profiling, Next-Generation Drugs and Precision Oncology,” joining other industry representatives including Zachary Boyd, MS, PhD, VP, Precision Medicine & Companion Diagnostics, J&J, Thousand Oaks, CA, USA, John Tarantino, JD, CEO, Iylon, USA, David Spetzler, MS, PhD, MBA, President, Caris Life Sciences, Paradise Valley, AZ, USA, and Navid Alipour, JD, MBA, CEO, Curematch, USA for a discussion of how genomic profiling, emerging therapeutics, and precision-oncology approaches may shape cancer care.
@WIN_Consortium @Dr_R_Kurzrock @SewantiLimaye @bcarneiro7 @DrSGraff @JerryAzzoli @LiangChengMD @IAbuGheidaMD @alshamsi2000 @VivekSubbiah @DrRoyHerbst @DCarboneMD @jrgralow @billdahutmd @LiaTsimberidou @RueterJens @LussierY
Wafik S. El-Deiry, MD, PhD, FACP retweeted
WATCH: FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated MSI-H/dMMR stage II/III locally advanced rectal cancer.
AZUR-1 (n=154):
• ORR 79% by independent central review
• 12-month sustained cCR 47% by central review; 68% by investigator
• 71% received dostarlimab alone with no other treatment and no progression
oncologytube.com/dostarlimab…
@AndreaCercek @GIMedOnc @skopetz @adasarimd @VanMorrisMD @KristenCiombor @RonaYaeger @KimmieNgMD @GIcancerDoc @CathyEngMD @marklewismd @NataliyaUboha @benweinbergmd @JeanneTie @WuGiOnc @drallysonocean @rutikamehtaMD @ShaalanBeg @GillSharlene @Sarbaji85064063 @DaisukeKotani @DraMartinezLago @TapiaJC1 @ilyassahinMD @ArndtVogel @realbowtiedoc @VivekSubbiah @Dr_R_Kurzrock @weldeiry @SeanLangenfeld @HassanRHashmiMD @JasonRLiuMD @yukiwadamd @SimranPolce @TrudyWuMD
Wafik S. El-Deiry, MD, PhD, FACP retweeted
“An outstanding global healthcare citizen who I believe will do a great job all around as Director-General of the World Health Organization.”
Wafik El-Deiry (@weldeiry), Founding Director of the Legorreta Cancer Center at Brown University, endorses Dr. Gevorg Tamamyan’s (@GevTamamyan) candidacy for Director-General of the World Health Organization (@WHO).
Read more on OncoDaily: oncodaily.com/positive/wafik…
Wafik S. El-Deiry, MD, PhD, FACP retweeted
During her talk at Rutgers on Oct 13, @TracyBethHoeg discussed her concerns about mFLUSIVA, the first mRNA-based influenza vaccine, which was recently approved by the FDA for adults 50 & older.
"personally I look at this and I wonder how could they say that the benefits of this outweigh the harms"
Wafik S. El-Deiry, MD, PhD, FACP retweeted
Whenever data don’t support the narrative, they use data-free scare models!
Yet another @nytimes hit piece citing @AnnalsofIM simulation study, arguing that postponing Hepatitis B birth dose for babies of mothers who are tested negative to Hep B will cause significant harm..
Looks more like a planned hit piece on the new (stayed) ACIP and @SecKennedy than serious science.
Very easy to uncover the grossly biased model’s assumptions:
1) Ignore the fact that the recommendation to postpone birth dose applied only to women who are tested negative (not ones not tested).
2) Assuming that the newly recommended policy by ACIP of shared decision making will lead to only 50 percent vaccination rate.
3) Assuming community infection prevalence and horizontal infection rates grossly unrealistic to the vast majority of US households/families.
What the study does not do is to validate the model against real data from the many developed countries that don’t have birth dose, including parts of Canada. Data-free models can give you any results you wish to have…
Equally importantly the model assumes no harm from giving a baby medical intervention on the first day of life…
The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post-Menopause
onlinelibrary.wiley.com/doi/…
Scientists uncover unexpected changes in ovaries as women age
New research reveals that ovaries continue changing decades after menopause, raising questions about their role in women's long-term health.
earth.com/science/scientists…





























